Edgar Filing: RASTETTER WILLIAM H - Form 4

	R WILLIAM H									
Form 4 November 13	3. 2018									
FORM	ГЛ	TATES SE				IGE (COMMISSION	OMB	PPROVAL 3235-0287	
Wasnington, D.C. 20549 Number:								rs per		
	ddress of Reporting Po R WILLIAM H	Syn					5. Relationship of Issuer	Reporting Per	son(s) to	
	(First) (Mi LUS THERAPEU' SCIENCE CENT	iddle) 3. D (Mo TICS 11/	Regulus Therapeutics Inc. [RGLS] 3. Date of Earliest Transaction (Month/Day/Year) 11/12/2018				(Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)			
SAN DIEGO	(Street) D, CA 92121		Amendment, Da d(Month/Day/Year)	-			6. Individual or Jc Applicable Line) _X_ Form filed by M Form filed by M Person	One Reporting Pe	erson	
(City)	(State) (Z	Zip)	Table I - Non-D	erivative S	ecurit	ies Acc	uired, Disposed of	, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Da any (Month/Day/Y	Code	on(A) or Dis (D) (Instr. 3, 4	sposed	of	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	11/12/2018		A	23,258		(<u>1</u>)	79,672 <u>(2)</u>	I	William H. Rastetter TTEE, Marisa Rastetter TTEE 9-2-2010 FBO Rastetter Family Trust	

Edgar Filing: RASTETTER WILLIAM H - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		e Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 92.04	11/12/2018		D	2,500 (2)) <u>(3)</u>	03/31/2023	Common Stock	2,500 (2)	
Stock Option (Right to Buy)	\$ 111.84	11/12/2018		D	1,458 (2)	3 (3)	06/09/2023	Common Stock	1,458 (2)	
Stock Option (Right to Buy)	\$ 74.64	11/12/2018		D	1,458 (2)	3 (3)	05/21/2024	Common Stock	1,458 (2)	

8. l De Sec (In

Stock Option (Right to Buy)	\$ 120.24	11/12/2018	D	1,458 (2)	<u>(3)</u>	06/08/2025	Common Stock	1,458 (2)
Stock Option (Right to Buy)	\$ 74.4	11/12/2018	D	3,051 (2)	<u>(3)</u>	05/31/2026	Common Stock	3,051 (2)
Stock Option (Right to Buy)	\$ 17.4	11/12/2018	D	2,500 (2)	(3)	05/30/2027	Common Stock	2,500 (2)
Stock Option (Right to Buy)	\$ 8.52	11/12/2018	D	6,250 (2)	(5)	05/16/2028	Common Stock	6,250 (2)



Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
RASTETTER WILLIAM H C/O REGULUS THERAPEUTICS INC 10614 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121	X							
Signatures								
Christopher Aker, Attorney in Fact	11/13/2018	3						

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I. The RSUs

- (1) vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date.
- (2) Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018.
- (3) The shares subject to the cancelled option were fully vested.
- (4) On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I.
- (5) The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant.

Date

Edgar Filing: RASTETTER WILLIAM H - Form 4

(6) The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.